Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06143436
Other study ID # CMUH112-REC3-157
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 20, 2023
Est. completion date May 19, 2025

Study information

Verified date December 2023
Source China Medical University Hospital
Contact Su-Tso Yang, M.D.
Phone 886-4-22052121
Email 002794@tool.caaumed.org.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Recently, TCM has played an important role in adjuvant therapy for lung cancer. TCM treatment is based on pattern identification, and constitution theory is also used as a tool for TCM to predict the disease progression. Although there have been many researchs related to the pattern identification and constitution of lung cancer, in view of the problems and limitations, further research on lung cancer patients in Taiwan is needed. This study aims to explore the correlation between TCM constitution, pattern identification, and other related factors in patients with primary lung cancer in Taiwan, hoping to reveal the disease characteristics of lung cancer in TCM theory. This study intends to interview subjects through attending physicians in the thoracic ward and outpatient clinic of the CMUH from November 20th, 2023 to May 19th , 2025, and the subjects will be included in this study after the researchers ask the subjects for consent. This study will collect the demographic data of the subjects (sex, age, BMI, smoking history) and disease-related clinical data (tumor stage, pathological type, gene mutation, tumor markers, other comorbidities), and the investigator will ask about the subjects' signs according to the Constitution in Chinese Medicine Questionnaire (CCMQ) , ask the subjects' symptoms according to the pattern identification table, obtain the data to analyze their distribution by descriptive statistics, and then analyze the correlation between them by analysis of variance and Chi-square test.


Recruitment information / eligibility

Status Recruiting
Enrollment 250
Est. completion date May 19, 2025
Est. primary completion date May 19, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Patients diagnosed with primary lung cancer. - Age greater than 18 years and less than 100 years. - After explanation, they agree to join this study and voluntarily sign the subject consent form, and can understand the content of the questionnaire. Exclusion Criteria: - Pregnant women. - Severe mental illness that affects the response to the questionnaire. - Has been treated (e.g., surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, etc.). - Concomitant with other uncured primary malignancies. - Patients with other serious primary diseases (such as: liver and kidney dysfunction, hematolymphatic system diseases, etc.). - Severe respiratory diseases that are not lung cancer (e.g. primary emphysema, interstitial fibrosis, etc.) .

Study Design


Intervention

Diagnostic Test:
Constitution in Chinese Medicine Questionnaire
Using questionnaire to collect data from new lung cancer patients.

Locations

Country Name City State
Taiwan China Medical University Hospital Taichung City

Sponsors (1)

Lead Sponsor Collaborator
China Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary TCM body constitution Ask about the subjects' signs according to the Constitution in Chinese Medicine Questionnaire (CCMQ) 20-30 minuts
Primary TCM pattern types Ask about the subjects' symptoms according to the pattern identification table 20-30 minuts
Secondary demographic data sex, age, BMI, smoking history 1 day
Secondary disease-related clinical data tumor stage, pathological type, gene mutation, tumor markers, other comorbidities 1 day
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05014477 - Therapy Strategies After LAA Occluder Device Embolization
Active, not recruiting NCT05909592 - Shoulder Injury Rate and Risk Among CrossFit Participants in Greece. Εfficacy of an Innovative Prevention Program.
Recruiting NCT02905552 - Myelodysplasic Syndromes and Risk Factors for Infection N/A
Recruiting NCT05788861 - Invasive Group A Streptococcal Infection
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed NCT05389540 - Rural South and Southeast Asia Household Health Survey
Not yet recruiting NCT05519657 - Incidence and Risk Factors of PPCs in Elderly Patients Undergoing Robot Assisted Laparoscopic Pelvic Surgery
Not yet recruiting NCT05564975 - Construction and Application of Pressure Injury Risk Prediction Model for Critically Ill Patients
Recruiting NCT04912739 - Targeted Health Dialogues in Primary Care
Completed NCT05535309 - Establishment of Risk Factors Model of Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium
Not yet recruiting NCT06118437 - Establishment and Validation of a Clinical Predictive Model for Gastrointestinal Cancer Screening Based on Patient-related Risk Factors
Recruiting NCT03713931 - PUMA Implementation 2
Recruiting NCT06441240 - Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.
Completed NCT00699725 - Adherence to Gastro-protection in Non-steroidal Anti-inflammatory Drug (NSAID) Using Patients N/A
Completed NCT00888030 - P-cresol: Correlation With Glomerular Filtration Rate and Outcome in Chronic Kidney Disease N/A
Not yet recruiting NCT06288724 - MOdifiable facTors to Improve VentilAtion ThErapy in ICU
Recruiting NCT06374849 - Intraoperative Sufentanil and Chronic Postsurgical Pain in Non-major Scheduled Abdominal Surgery Phase 4
Completed NCT04683380 - Robustness Predictive Factors in People Aged Over 75 Years After Going to the Emergency Room (ROB-U)
Completed NCT02884167 - Multidimensional Risk Factor Assessment in Constipation N/A
Not yet recruiting NCT05473403 - Validation of a Prognostic Score for Steroid Therapy Response in Acute Severe Autoimmune Hepatitis N/A